Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 8963 results
Found 8963 results.

Adenine

Hu Z, Hatano H, Hammond SP, et al. "Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase." J. Acquir. Immune Defic. Syndr.. 2007;45(5):494-500.
Bartlett JA, Chen S-S, Quinn JB. "Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview." HIV Clin Trials. 2007;8(4):221-6.
Torriani FJ, Komarow L, Parker RA, et al. "Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s." J. Am. Coll. Cardiol.. 2008;52(7):569-76.
McComsey GA, Daar ES, O'Riordan MA, et al. "Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202." J. Infect. Dis.. 2013;207(4):604-11.
Asmelash A, Zheng Y, Kaloustian KWools, et al. "Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa." BMC Infect. Dis.. 2014;14:331.
Lockman S, Hughes MD, McIntyre J, et al. "Antiretroviral therapies in women after single-dose nevirapine exposure." N. Engl. J. Med.. 2010;363(16):1499-509.
McComsey GA, Kitch D, Daar ES, et al. "Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir." AIDS. 2012;26(11):1371-85.
Grant PM, Tierney C, Budhathoki C, et al. "Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202." HIV Clin Trials. 2013;14(6):284-91.
Andrade A, Rosenkranz SL, Cillo AR, et al. "Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248." J. Infect. Dis.. 2013;208(6):884-91.
Tungsiripat M, Kitch D, Glesby MJ, et al. "A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206." AIDS. 2010;24(11):1781-4.
Lennox JL, Landovitz RJ, Ribaudo HJ, et al. "Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial." Ann. Intern. Med.. 2014;161(7):461-71.
Mwafongo A, Nkanaunena K, Zheng Y, et al. "Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine." AIDS. 2014;28(8):1135-42.
Gulick RM, Lalama CM, Ribaudo HJ, et al. "Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression." AIDS. 2007;21(7):813-23.
Funderburg NT, Andrade A, Chan ES, et al. "Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine." PLoS ONE. 2013;8(12):e83514.
Kang M, Hollabaugh K, Pham V, et al. "Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort." J. Acquir. Immune Defic. Syndr.. 2014;66(2):172-80.
Delahunty T, Bushman L, Fletcher CV. "Sensitive assay for determining plasma tenofovir concentrations by LC/MS/MS." J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.. 2006;830(1):6-12.
Wyatt CM, Kitch D, Gupta SK, et al. "Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine." J. Acquir. Immune Defic. Syndr.. 2014;67(1):36-44.
Parikh UM, Bacheler L, Koontz D, Mellors JW. "The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations." J. Virol.. 2006;80(10):4971-7.
Porter KA, Cole SR, Eron JJ, et al. "HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study." Antimicrob. Agents Chemother.. 2012;56(2):995-1000.
Gross R, Tierney C, Andrade A, et al. "Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial." Arch. Intern. Med.. 2009;169(13):1224-32.

Pages